Brief: Oncolytics Biotech Inc Announces Alignment With FDA On Pivotal Anal Cancer Study
April 27 (Reuters) - Oncolytics Biotech Inc ONCY.O: ONCOLYTICS BIOTECH INC - ANNOUNCES ALIGNMENT WITH FDA ON PIVOTAL ANAL CANCER STUDY - SEC FILING Source text: [ID:n0001129928-26-000026] Further company coverage: ONCY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer